Name | Title | Contact Details |
---|---|---|
Matt Paulson |
Development Chief of Staff | Profile |
Lindsay Yamamoto |
Director, Human Resources | Profile |
Danielle Olander |
Senior Vice President, Talent and Systems Development | Profile |
Ludesi is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
Our Q Exam is based on landmark systems biology research done at Stanford University. In about 75 minutes, we take blood, saliva, urine and a non-invasive whole-body scan from which we measure over 3000 clinically-relevant genetic, chemical, and anatomical biomarkers to build the world`s most comprehensive quantitative snapshot of your health at a point in time.
Cofactor Genomics is pioneering the use of RNA to diagnose disease.
Intabio provides an analytical platform to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing.